SCHEMBL19862423

SCHEMBL19862423

COc1cc(/C=C2/C(C)=C(CC(=O)N(C)CCN(C)C)c3cc(OC)ccc32)cc(OC)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 11/20 0.49
RXRA P19793 4/20 0.44
MAPT P10636 2/20 0.38
USP2 O75604 1/20 0.38
PKM P14618 1/20 0.38
KMT2A Q03164 1/20 0.38
LCK P06239 1/20 0.37
PRKACA P17612 1/20 0.37
PRKACG P22612 1/20 0.37
PRKACB P22694 1/20 0.37
EGFR P00533 1/20 0.36
CYP1A2 P05177 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
DRD1 P21728 1/20 0.36
PTGS1 P23219 1/20 0.36
MAPK1 P28482 1/20 0.36
PTGS2 P35354 1/20 0.36
OPRM1 P35372 1/20 0.36
PSEN1 P49768 1/20 0.36
PSEN2 P49810 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17854899 0.91 PPARG (0.44) PPARGRXRALCKPRKACAPRKACG
SCHEMBL17847838 0.89 RXRA (0.46) PPARGRXRAMAPTUSP2KMT2A
SCHEMBL17847842 0.89 RXRA (0.46) PPARGRXRAMAPTUSP2KMT2A
SCHEMBL17854911 0.87 PPARG (0.52) PPARGRXRAMAPTKMT2AEGFR
SCHEMBL24740945 0.86 RXRA (0.44) PPARGRXRAMAPTKMT2ALCK
SCHEMBL17854898 0.82 PPARG (0.69) PPARGRXRAMAPTKMT2AEGFR
SCHEMBL21806022 0.82 PPARG (0.69) PPARGRXRAMAPTKMT2AEGFR
SCHEMBL21376111 0.77 PPARG (0.50) PPARGRXRAMAPTKMT2AEGFR
SCHEMBL17854864 0.76 PPARG (0.46) PPARGRXRAMAPTKMT2ALCK
SCHEMBL17847950 0.76 PPARG (0.46) PPARGRXRAMAPTKMT2ALCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11198679-B2 Method of treating or preventing Ras-mediated diseases ADT PHARMACEUTICALS, LLC (US) 2021-12-14 US disclosed
US-20200223817-A1 METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES ADT PHARMACEUTICALS, LLC (US) 2020-07-16 US disclosed
EP-3666268-A1 METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES ADT Pharmaceuticals, LLC (US) 2020-06-17 EP disclosed
EP-3233071-B1 METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES ADT PHARMACEUTICALS LLC (US) 2019-09-18 EP disclosed
US-20180044314-A1 METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES ADT PHARMACEUTICALS INC (US) 2018-02-15 US disclosed
US-20180044314-A1 METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES ADT PHARMACEUTICALS INC (US) 2018-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11198679-B2 Method of treating or preventing Ras-mediated diseases KRAS, NRAS, HRAS PPARG 1654/4885RXRA 62/4885MAPT 4816/4885
US-20180044314-A1 METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES KRAS, NRAS, HRAS PPARG 1654/4885RXRA 62/4885MAPT 4816/4885
US-20200223817-A1 METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES KRAS, NRAS, HRAS PPARG 1654/4885RXRA 62/4885MAPT 4816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.